Journal Watch · The EMBO Journal · 2026

ALYREF condensation stabilizes m<sup>5</sup>C-modified PARP10 mRNA and promotes PI3K-AKT signaling in ovarian cancer.

Together, these findings suggest that ALYREF phase separation facilitates the malignant progression of ovarian cancer by promoting PARP10 expression and thereby enhancing PARP10-dependent proliferative pathways in a m<sup>5</sup>C-dependent manner.

Zhao H, Wei Q, Luo Z et al.The EMBO Journal3 min readPharma relevance 65/100

DOI: 10.1038/s44318-025-00657-0PMID: 41326692Study type: preclinical (animal / model) study

TL;DR

Together, these findings suggest that ALYREF phase separation facilitates the malignant progression of ovarian cancer by promoting PARP10 expression and thereby enhancing PARP10-dependent proliferative pathways in a m<sup>5</sup>C-dependent manner.

Key findings

  • Further, ALYREF forms condensates in the nucleus of ovarian cancer cells, and depletion or mutation of ALYREF's intrinsically disordered regions rescues its control on PARP10 mRNA nucleoplasmic distribution and stability, reduces tumor growth and is required for promotion of ovarian cancer aggressiveness and proliferation.
  • Finally, ALYREF and PARP10 expression correlate with poor prognosis in ovarian cancer patients.
  • Together, these findings suggest that ALYREF phase separation facilitates the malignant progression of ovarian cancer by promoting PARP10 expression and thereby enhancing PARP10-dependent proliferative pathways in a m<sup>5</sup>C-dependent manner.

What they did

ALYREF is elevated in ovarian cancer patient samples, and its depletion reduces ovarian tumorigenesis and metastasis in mice in a m<sup>5</sup>C-dependent manner. Mechanistically, ALYREF binds to the m<sup>5</sup>C-modified mRNA of ADP-ribosyltransferase PARP10, competing with exosome complex component MTR4, and enhancing the stability and nuclear export of PARP10 mRNA.

Full abstract (original)

Background: The role of epigenetic regulation of RNAs in the tumorigenesis remains incompletely understood. This study uncovers a critical function of the 5-methylcytosine (m<sup>5</sup>C) RNA modification reader protein ALYREF (also termed, ALY; BEF) in ovarian cancer.

What they did: ALYREF is elevated in ovarian cancer patient samples, and its depletion reduces ovarian tumorigenesis and metastasis in mice in a m<sup>5</sup>C-dependent manner. Mechanistically, ALYREF binds to the m<sup>5</sup>C-modified mRNA of ADP-ribosyltransferase PARP10, competing with exosome complex component MTR4, and enhancing the stability and nuclear export of PARP10 mRNA.

Results & conclusions: Further, ALYREF forms condensates in the nucleus of ovarian cancer cells, and depletion or mutation of ALYREF's intrinsically disordered regions rescues its control on PARP10 mRNA nucleoplasmic distribution and stability, reduces tumor growth and is required for promotion of ovarian cancer aggressiveness and proliferation. Finally, ALYREF and PARP10 expression correlate with poor prognosis in ovarian cancer patients. Together, these findings suggest that ALYREF phase separation facilitates the malignant progression of ovarian cancer by promoting PARP10 expression and thereby enhancing PARP10-dependent proliferative pathways in a m<sup>5</sup>C-dependent manner.

Abstract © the authors / The EMBO Journal (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s44318-025-00657-0 · PubMed 41326692.

Why it matters for pharma & biotech

  • Directly relevant to teams in mRNA / delivery technology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: mRNA / delivery technology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this The EMBO Journal study find?

Together, these findings suggest that ALYREF phase separation facilitates the malignant progression of ovarian cancer by promoting PARP10 expression and thereby enhancing PARP10-dependent proliferative pathways in a m<sup>5</sup>C-dependent manner.

What type of study is this?

It is a preclinical (animal / model) study, published in The EMBO Journal in 2026. ALYREF is elevated in ovarian cancer patient samples, and its depletion reduces ovarian tumorigenesis and metastasis in mice in a m<sup>5</sup>C-dependent manner.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s44318-025-00657-0. PubMed ID: 41326692. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Zhao H, Wei Q, Luo Z et al.. ALYREF condensation stabilizes m&lt;sup&gt;5&lt;/sup&gt;C-modified PARP10 mRNA and promotes PI3K-AKT signaling in ovarian cancer.. The EMBO Journal (2026). DOI: 10.1038/s44318-025-00657-0.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/alyref-condensation-stabilizes-m-lt-sup-gt-5-lt-sup-gt-c-modified-parp10-006570/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides